150
Participants
Start Date
March 31, 2012
Primary Completion Date
April 30, 2013
Study Completion Date
April 30, 2013
Rotigotine
"Transdermal patch containing Rotigotine formulated in an adhesive matrix. Subjects were to be treated with their optimal dose which consisted of one of the dose strengths below:~Rotigotine 1 mg /24 hr, Rotigotine 2 mg/ 24 hr, Rotigotine 3 mg/ 24 hr, One patch every 24 hours~7 weeks (titration plus maintenance)"
Placebo
"Placebo patches titrated from 1 mg/ 24 hr - 3 mg/ 24 hr or until effective or maximum dose was reached.~Placebo 1 mg/ 24 hr, Placebo 2 mg/ 24 hr, Placebo 3 mg/ 24 hr, one patch every 24 hours.~7 weeks (titration plus maintenance)"
006, Birmingham
013, Jasper
021, Gilbert
014, Little Rock
010, Oceanside
004, Orange
002, Tampa
012, Macon
008, Destrehan
017, Brighton
016, Brockton
019, Kalamazoo
015, St Louis
007, West Seneca
018, Cincinnati
009, West Chester
003, Austin
005, San Antonio
Lead Sponsor
UCB Pharma
INDUSTRY